
    
      Purpose of the study: A randomized, triple-blind, pilot clinical trial has been designed to
      evaluate the effectiveness of trehalose on reducing the symptoms in AD patients. Study
      intervention: twenty patients with Alzheimer's disease were randomly divided into an
      intervention and a control group. Trehalose will be administrated intravenously (15 g/week)
      for 12 weeks in the intervention group and the control group will be received normal saline
      as a placebo.
    
  